Flare Therapeutics logo

Flare Therapeutics

Trailblazing the path to drugging transcription factors to discover precision medicines for cancer & other disease areas

62 employees · est. 2021 · Cambridge, United States

VS
Kronos Bio logo

Kronos Bio

We’re focused on creating a world where no life is cut short by cancer or other serious diseases.

70 employees · est. 2017 · San Mateo, United States

Kronos Bio is the older company (2021 vs 2017).

Side-by-Side Comparison

Flare Therapeutics Kronos Bio
Founded
2021 2017 older
Headquarters
Cambridge, United States San Mateo, United States
Employees
62 70
Industry
Biopharma, Biotechnology, Health Care Biotechnology, Health and Wellness
Funding Stage
Series B Private Equity
Total Funding
$205.00M $278.00M
Funding Rounds
2 3
Services
Development of small molecules for cancer treatment, Research and innovation in transcriptional control Not tracked yet
Target Customers
Medical professionals, Oncology researchers, Healthcare institutions, Patients with cancer Not tracked yet
Taxonomy
Precision Medicines, Transcription Factors, Oncology, Drug Discovery, Small Molecule Inhibitors, Urothelial Cancer, Androgen Receptor Degrader, Transcription Factor Regulation, Integrated Discovery Platform, Emerging Pipeline, Precision Oncology, Neurology, Rare Genetic Disorders, Immunology, Inflammation Biopharmaceutical Company, Clinical-stage, Therapeutics, CDK9 Inhibitor, Transcription Factor, Oncology, Cancer Treatment, Myc-dependent Tumors, Transcriptional Addiction, Discovery Collaboration, Genentech Partnership, P300 KAT Domain, Multiple Myeloma, Transcriptional Targets, Precision Medicine
Website
flaretx.com kronosbio.com
Flare Therapeutics logo

About Flare Therapeutics

Flare Therapeutics, founded in 2021, is trailblazing the path to drugging transcription factors to discover precision medicines for cancer and other disease areas. This United States-based company is strategically positioned in the biopharma, biotechnology, health care, and life sciences industries....

Kronos Bio logo

About Kronos Bio

Kronos Bio is a clinical-stage biopharmaceutical company with a mission to combat cancer and serious diseases by targeting dysregulated transcription. The company's current pipeline includes KB-0742, a CDK9 inhibitor under evaluation for MYC-dependent tumors and KB-9558, targeting the KAT domain of...

We will tell you when either one moves

BounceWatch watches Flare Therapeutics and Kronos Bio for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Flare Therapeutics and Kronos Bio — by email.

Frequently Asked Questions

Flare Therapeutics — Trailblazing the path to drugging transcription factors to discover precision medicines for cancer & other disease areas. Kronos Bio — We’re focused on creating a world where no life is cut short by cancer or other serious diseases.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Flare Therapeutics has raised $205.00M while Kronos Bio has raised $278.00M.
Flare Therapeutics and Kronos Bio operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Flare Therapeutics with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Flare Therapeutics on 11 Mar 2026, and Kronos Bio on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy